Kristen S Hill (Kristen Hill)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Plasmodium Falciparum

Top Venues

Diagnostics (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

J Robert McCorkle, Rebecca Ahn, Connie D Cao, Kristen S Hill, Charles S Dietrich, Jill M Kolesar
Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer. Cancers 16 (7) (2024)
J Robert McCorkle, Rebecca Ahn, Connie D Cao, Kristen S Hill, Charles S Dietrich, Jill M Kolesar
Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer. Cancers 16 (7) (2024)
J Robert McCorkle, Rebecca Ahn, Connie D Cao, Kristen S Hill, Charles S Dietrich, Jill M Kolesar
Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer. Cancers 16 (7) (2024)
Hannah G McDonald, Megan M Harper, Kristen S Hill, Anqi Gao, Angelica L Solomon, Charles J Bailey, Miranda Lin, Mautin Barry-Hundeyin, Michael J Cavnar, Samuel H Mardini, Prakash J Pandalai, Reema A Patel, Jill M Kolesar, Justin A Rueckert, Lawrence Hookey, Mark Ropeleski, Shaila J Merchant, Joseph Kim, Mei Gao
Creation of EGD-Derived Gastric Cancer Organoids to Predict Treatment Responses. Cancers 15 (11) (2023)
Anthony McDowell, Kristen S Hill, J Robert McCorkle, Justin Gorski, Ameen A Salahudeen, Frederick Rand Ueland, Jill M Kolesar, Jill M Kolesar
Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment. Diagnostics (Basel, Switzerland) 11 (3) (2021)
Kristen S Hill, Anthony McDowell, J Robert McCorkle, Erin Schuler, Sally R Ellingson, Rina Plattner, Jill M Kolesar
KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer. Cancers 13 (8) (2021)